JamesScottAndrewsMD
Rheumatology • Birmingham, ALClinical Fellow, Internal Medicine, UCSF School of Medicine
Are you Dr. Andrews?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 47 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
2000 6th Ave S
Birmingham, AL 35233Phone+1 205-934-9999
Summary
- Dr. James Andrews, MD is a rheumatologist in Birmingham, Alabama. He is currently licensed to practice medicine in Alabama, Washington, and California. He is affiliated with UW Medicine/University of Washington Medical Center and is a Clinical Fellow at UCSF School of Medicine.
Education & Training
University of California (San Francisco)Fellowship, Rheumatology, 2012 - 2014- University of California (San Francisco)Residency, Internal Medicine, 2009 - 2012
Stanford University School of MedicineClass of 2009
Certifications & Licensure
CA State Medical License 2010 - Present
AL State Medical License 2023 - 2025
WA State Medical License 2015 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Rheumatology
Clinical Trials
- Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial) Start of enrollment: 2022 May 01
Publications & Presentations
PubMed
- Epidemiology of myositis.Fnu Duremala, Eleni Tiniakou, James Andrews
Current Opinion in Rheumatology. 2025-03-01 - 2 citationsAssessment of the Impact of RNase in Patients With Severe Fatigue Related to Post-Acute Sequelae of SARS-CoV-2 Infection: A Randomized Phase 2 Trial of RSLV-132.James S Andrews, Jim B Boonyaratanakornkit, Eva Krusinska, Suzanne Allen, James A Posada
Clinical Infectious Diseases. 2024-09-26 - 4 citationsFrailty and Risk of Serious Infections in Patients With Rheumatoid Arthritis Treated With Biologic or Targeted-Synthetic Disease-Modifying Antirheumatic Drugs.Namrata Singh, Laura S Gold, Jiha Lee, Katherine D Wysham, James S Andrews
Arthritis Care & Research. 2024-05-01
Press Mentions
Drugmakers, Scientists Begin the Hunt for Long COVID TreatmentsMarch 26th, 2022- Drugmakers, Scientists Begin the Hunt for Long COVID TreatmentsMarch 25th, 2022
- Tackling the Unknowns of Long-Haul COVID-19January 26th, 2022
